MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16

OBJECTIVES: To identify the first time point of an MRI-verified response to certolizumab pegol (CZP) therapy in patients with rheumatoid arthritis (RA). METHODS: Forty-one patients with active RA despite disease-modifying antirheumatic drug therapy were randomised 2:1 to CZP (CZP loading dose 400 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Østergaard, M, Jacobsson, L T H, Schaufelberger, C, Hansen, M Sejer, Bijlsma, J W J, Dudek, A, Rell-Bakalarska, M, Staelens, F, Haake, R, Sundman-Engberg, B, Bliddal, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431335/
https://www.ncbi.nlm.nih.gov/pubmed/25512675
http://dx.doi.org/10.1136/annrheumdis-2014-206359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431335/
https://www.ncbi.nlm.nih.gov/pubmed/25512675
http://dx.doi.org/10.1136/annrheumdis-2014-206359

Ejemplares similares